Charles Newton
Directeur Financier/CFO chez LYELL IMMUNOPHARMA, INC.
Fortune : 90 418 $ au 30/04/2024
Postes actifs de Charles Newton
Sociétés | Poste | Début | Fin |
---|---|---|---|
LYELL IMMUNOPHARMA, INC. | Directeur Financier/CFO | 01/02/2021 | - |
COHERUS BIOSCIENCES, INC. | Directeur/Membre du Conseil | 05/05/2022 | - |
Independent Dir/Board Member | 05/05/2022 | - | |
2SEVENTY BIO, INC. | Directeur/Membre du Conseil | 20/03/2024 | - |
Independent Dir/Board Member | 20/03/2024 | - | |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Directeur/Membre du Conseil | 19/07/2023 | - |
Independent Dir/Board Member | 19/07/2023 | - |
Historique de carrière de Charles Newton
Anciens postes connus de Charles Newton
Sociétés | Poste | Début | Fin |
---|---|---|---|
Credit Suisse Group AG /US/
Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Directeur Général | 01/09/2010 | 01/11/2015 |
MORGAN STANLEY | Corporate Officer/Principal | 01/06/1996 | 01/09/2010 |
BofA Securities, Inc.
BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Corporate Officer/Principal | - | - |
Formation de Charles Newton
Tuck School of Business at Dartmouth | Masters Business Admin |
Miami University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 10 |
Opérationnelle
Director/Board Member | 3 |
Independent Dir/Board Member | 3 |
Corporate Officer/Principal | 2 |
Sectorielle
Health Technology | 5 |
Finance | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 4 |
---|---|
LYELL IMMUNOPHARMA, INC. | Health Technology |
COHERUS BIOSCIENCES, INC. | Health Technology |
MORGAN STANLEY | Finance |
2SEVENTY BIO, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Credit Suisse Group AG /US/
Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Finance |
BofA Securities, Inc.
BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Finance |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Bourse
- Insiders
- Charles Newton
- Expérience